Robust Glycemic Control & Cardio-Renal Protection: Meeting the Advanced Needs of Indian Uncontrolled T2D with Empagliflozin, Sitagliptin, Metformin Dr. Nilanjan Sengupta28 Jan 2026 12:45 PM ISTIndia has an estimated 90 million people living with T2D [1] amid rising obesity and doubled management costs. Uncontrolled T2DM and early-onset...
Dapagliflozin and Sitagliptin FDC in T2D with Heart Failure: 2025 Indian Practice Review Dr. Santosh H.S.17 Jan 2026 11:39 AM ISTAmong India's 89.8 million people with T2D [1], heart failure incidence reaches approximately 50%, with 33% higher hospitalization risk versus...
Explainer video: Advise- Educating Patients about Addressing Glycemic and Weight Goals Deeksha Bhandari11 Nov 2025 11:45 AM ISTTalking about excess weight with people living with type 2 diabetes can be sensitive, but it is an important part of diabetes care. Evidence shows...
A Hidden Epidemic: Addressing Visceral Fat and Insulin Resistance in Non-Obese T2DM with Pioglitazone-Based Therapies Dr. K M Suryanarayana VSM5 Nov 2025 11:15 AM ISTMetabolically unhealthy non-obese individuals (MUNO) comprise around 20% of the normal-weight population and have a 3.14-fold higher risk of...
Dapagliflozin and Sitagliptin FDC: Exploring Early Initiation Benefits In Young Newly Diagnosed T2D in India Dr. Rajiv Kovil1 Nov 2025 10:34 AM ISTType 2 diabetes (T2D) is a growing epidemic in India. India has 101 million people with diabetes and 136 million with prediabetes, with disease onset...
The Forgotten Insulin Sensitizer: Revisiting Pioglitazone for Metabolically Unhealthy Non-Obese (MUNO) Indians with T2DM Dr. Arvind Gupta25 Aug 2025 10:56 AM ISTMUNO Indian Phenotype: A Silent High-Risk Candidate The Metabolically Unhealthy Non-Obese (MUNO) phenotype is a silent but high-risk profile,...
Prediabetes and MASLD : An Overlapping Spectrum of Metabolic Risk Dr. Anusha N D14 July 2025 11:01 AM ISTConverging Burden of Prediabetes and MASLD: Prediabetes is associated with a nearly 4-fold higher risk of MASLD. (1) Approximately 33% of Indian...
Aspirin in Primary Prevention: Prudent Guideline-Based Approach Prof. (Dr.) J.P.S. Sawhney13 Jun 2025 11:44 AM ISTAspirin in Primary Prevention: Need for Delineating High CV-Risk, Low-Bleeding-Risk Profiles: Aspirin in primary prevention requires a nuanced,...
Micro Labs Launches Sitanorm-E, Sitagliptin-Empagliflozin FDC for Uncontrolled Type 2 Diabetes in India Deeksha Bhandari6 Jun 2025 12:11 PM ISTMicro Labs has announced the launch of Sitanorm-E, a fixed-dose combination (FDC) of Sitagliptin and Empagliflozin. The combination is formulated to...
ADA/CRP ratio may help differentiate Tuberculous from Malignant pleural effusion Aditi10 Oct 2023 8:00 PM ISTTuberculous pleural effusion (TPE) and malignant pleural effusion (MPE) display similar cytological and biochemical pictures, including adenosine...
American Diabetes Association releases guideline update on NAFLD in People with diabetes MD Brand Connect13 July 2023 11:15 AM ISTPioglitazone/GLP1 RA are the preferred agents for the treatment of hyperglycemia in people with T2DM diabetes with NAFLD or those at high risk of...
Important Updates to the Standards of Medical Care in Diabetes-2022 Incorporate New Evidence Dr. Kamal Kant Kohli13 Jun 2022 9:15 AM ISTToday, the American Diabetes Association (ADA) published important updates to the Standards of Medical Care in Diabetes-2022 (Standards of Care), in...
